Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Proteasome subunit PSMD1 is a key myeloma therapeutic target; depletion decreases cancer cell viability, induces polyubiquitinated protein accumulation, promotes apoptosis in vitro and in vivo, and overcomes drug resistance.”
Title: Proteasome Subunit PSMD1 is a Key Therapeutic Target in Multiple Myeloma
Authors: Ting Du, Teng Fang, Sindhu Pillai, Arghya Ray, Minxing Wang, Xueping Wan, Kenneth Wen, Yuntong Liu, Jingyu Xu, Md Abu Musa, Xiangdong Liu, Mariateresa Fulciniti, Nikhil Munshi, Filip Garbicz, Ruben D. Carrasco, Yao Yao, Zhongkun Zhang, Yan Song, Kenneth Anderson
You can read the Full Article in Blood.
You can find more posts featuring Robert Orlowski on OncoDaily.